TuHURA Biosciences HURA

TuHURA Biosciences, Inc. is a phase 3 clinical stage immuno-oncology company focused on developing novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company leverages three proprietary technology platforms: Immune Fx (IFx), which uses innate immune agonist technology to make tumor cells appear bacterial; a TBS-2025 VISTA-inhibiting antibody acquired through the purchase of Kineta, Inc.; and a Delta Opioid Receptor (DOR)-targeted antibody-drug conjugate platform aimed at modulating myeloid-derived suppressor cells. Its lead candidate, IFx-2.0, is an intratumoral plasmid DNA encoding an immunogenic gram-positive bacterial protein that is being evaluated in a pivotal Phase 3 trial as an adjunct to pembrolizumab for first-line treatment of advanced or metastatic Merkel cell carcinoma under an FDA Special Protocol Assessment agreement. The trial, initiated in June 2025, expects enrollment over 18 to 24 months with topline data anticipated 6 to 7 months after the last patient is enrolled.

Revenue generation primarily stems from licensing agreements and collaborative arrangements that provide upfront payments, milestone royalties, and ongoing royalties. TuHURA received an initial, non-refundable license fee of $100,000 and a second fee of $30,000 under its 2019 exclusive license agreement with the Moffitt Cancer Center, plus a $12,500 fee under the 2021 Moffitt agreement and a $50,000 upfront fee under the 2022 West Virginia University Research Corporation agreement. In addition to these fees, the company is eligible for milestone payments ranging from $150,000 to $5.0 million based on clinical and sales milestones, and it owes royalties calculated as a low-to-mid single-digit percentage of net sales of licensed products. Collaborative research, such as the agreement with Merck to evaluate TBS-2025 in combination with pembrolizumab, also provides funding and resource support for clinical development.

TuHURA occupies a specialized niche within the competitive immuno-oncology landscape, where it contends with large established firms such as Merck & Co., Bristol-Myers Squibb, and Roche, as well as numerous biotechnology companies developing checkpoint inhibitor enhancers and immunomodulatory agents. The company’s competitive advantage derives from its three distinct platforms that attack different resistance mechanisms: IFx restores innate immune sensing of tumors, TBS-2025 blocks the immunosuppressive VISTA checkpoint on myeloid cells, and the DOR-targeted ADC reprograms myeloid-derived suppressor cells to reduce their inhibitory effects. Preclinical data show that the DOR is highly expressed on tumor-associated macrophages and myeloid-derived suppressor cells, and that its inhibition can shift the tumor microenvironment toward an immunogenic state. Furthermore, the company targets patient populations with significant unmet need, such as the approximately 4,245 individuals in the United States and 7,049 in the seven major European markets expected to be diagnosed with advanced Merkel cell carcinoma by 2027, a figure projected to rise to 15,262 by 2034 according to DelveInsight. Its focus on overcoming both primary and acquired resistance differentiates it from approaches that merely enhance existing checkpoint blockade.

The company’s customer base consists primarily of patients enrolled in its clinical trials, academic research partners, and pharmaceutical collaborators with whom it conducts joint development efforts. TuHURA works closely with the Moffitt Cancer Center and West Virginia University to advance its DOR technology, while its collaboration with Merck supports the clinical evaluation of TBS-2025 in combination with pembrolizumab. Manufacturing of clinical trial material is managed through relationships with contract development and manufacturing organizations, including Samsung Biologics for TBS-2025 drug substance and product. Ultimately, the therapies aim to serve individuals with advanced solid tumors and hematologic malignancies who have limited responses to current immunotherapies, addressing a critical gap in the oncology treatment landscape.